MIGDAL HA'EMEQ, ISRAEL, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced today that it was granted a patent by the U.S. Patent and Trademark Office for its composition of Vayacog® and its use in age-associated memory impairment and mild cognitive impairment.
"We are very pleased with the patent granted related to Vayacog®, one of our leading products intended for the dietary management of disorders related to cognitive or mental conditions. We believe this patent is evidence of Enzymotec's leading research and development initiatives and strengthens Vayacog's® position in the United States and other territories," said Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec Ltd. "We remain focused on building our intellectual property assets and delivering premier products to our customers around the world."
Vayacog® is an orally administered prescription medical food for the clinical dietary management of certain lipid imbalances associated with early memory impairment.
The Company has been granted over 50 patents and has applications for more than 100 additional patents pending worldwide.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies.
Forward Looking Statement
This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: a high proportion of the sales of our InFat product is sold to end users by a single company in China; we rely on our Swedish joint venture partner to manufacture InFat, and certain matters related to the joint venture are or, based on communications from our joint venture partner, are the subject of disagreement; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; we are dependent on a single facility that houses the majority of our operations; we may not be able to expand our production or processing capabilities or satisfy growing demand; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we are subject to significant and increasing government regulations regarding the sale and marketing of our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; we are currently subject to litigation, and in the future may become subject to additional litigation, regarding intellectual property rights; and other factors discussed under the heading "Risk Factors" in the Company's final prospectus for its initial public offering filed with the Securities and Exchange Commission on September 30, 2013. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: ICR, LLC Katie Turner 646-277-1228 -or- John Mills 310-954-1105 John.Mills@icrinc.comSource:Enzymotec Ltd.